The drug will be manufactured at the Granules manufacturing facility in Chantilly, Virginia, Granules said in an exchange filing.
According to IQVIA Health, Dexmethylphenidate HCl ER Capsules had US sales of approximately $556 million for the most recent twelve months ending in July 2020.
Granules India's stock hit a record high of Rs 384 on Thursday. In the past three months, it has rallied 86 per cent, as compared to 13.5 per cent rise in the S&P BSE Sensex.
On August 22, Granules India had announced that its subsidiary company Granules Pharmaceuticals Inc had received approval from the US Food & Drug Administration (US FDA) for Ramelteon Tablets 8 mg, a bioequivalent to the reference listed drug product (RLD), Rozerem Tablets, 8 mg, of Takeda Pharmaceuticals USA.
"Ramelteon Tablets are used for the treatment of insomnia characterised by difficulty with sleep onset. Ramelteon Tablets had US sales of approximately $33 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health," it said.
At 09:21 am, the stock was trading 2 per cent higher at Rs 367 on the BSE, against 0.18 per cent gain in the Sensex. A combined 696,000 equity shares have changed hands on the counter on the NSE and BSE, so far.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in